NTRA Natera, Inc. Common Stock Loading...

From DGX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Jul 23 ◎
Jim Davis Chairman, CEO and President, Quest Diagnostics Incorporated DGX Q2 FY26 call
Quest's Haystack MRD test received New York State approval; management noted only one other company has a tumor-informed MRD test cleared by NY State, implying a competitive edge. — Positions Quest as a leader in the MRD space alongside Natera (Signatera), potentially pressuring Guardant's Reveal and other naïve tests.
NTRA
MED

About NTRA Analyst Coverage

Buzzberg tracks NTRA (Natera, Inc. Common Stock) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Jim Davis.